Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 10/20 | 0.34 |
| ▸ | PDE1A | P54750 | 2/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29344298 | 0.90 | CYP4F2 (0.41) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL25372582 | 0.88 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30542395 | 0.88 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL25372579 | 0.88 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL31127808 | 0.86 | RXRA (0.38) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21195793 | 0.86 | CYP4F2 (0.45) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL19948345 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL24460667 | 0.84 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29563167 | 0.84 | CYP4F2 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30922447 | 0.84 | RXRA (0.40) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709371-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4615847-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2024233776-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME LLC (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024107686-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024103010-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CYP4F2 4059/4885CYP4A11 1348/4885RXRA 1531/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | CYP4F2 4455/4885CYP4A11 2667/4885RXRA 3377/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CYP4F2 4059/4885CYP4A11 1348/4885RXRA 1531/4885 |
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | CYP4F2 4690/4885CYP4A11 4627/4885RXRA 3326/4885 |
| US-20240294551-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CYP4F2 4059/4885CYP4A11 1348/4885RXRA 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.